On Thursday, Following Stocks were among the “Top Gainers” In U.S. Stock Exchange: IGI Laboratories, Inc (NYSEMKT:IG), Agenus Inc (NASDAQ:AGEN), Ironwood Pharmaceuticals, Inc (NASDAQ:IRWD), Agios Pharmaceuticals Inc (NASDAQ:AGIO)
IGI Laboratories, Inc (NYSEMKT:IG)’s shares picked up 4.96%, and closed at $8.67. The stock has price to sale ratio of 13.59, however, price to book ratio is 11.72. With recent incline, the year-to-date (YTD) performance reflected a 51.31% gain above last year. During the past month the stocks lose -21.40%, bringing three-month performance to -1.25% and six-month performance to 12.74%. The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
IGI Laboratories, Inc. develops, manufactures, and markets topical formulations in the United States. The company sells its generic topical pharmaceutical products under the IGI label. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, in addition to for over-the-counter (OTC) and cosmetic markets. The company’s products are used in various applications from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema.
Agenus Inc (NASDAQ:AGEN), raised 4.91%, and closed at $5.55. The company holds the market capitalization of $374.32M. For the last twelve months, the stock was able to keep return on equity at -124.40%, while return on assets at -62.10%, in response to its return on investment at -1007.00%. Its 20-day moving average gained 6.00%, above 50-day moving average of 8.27%, above 200-day moving average of 50.62% from the latest market price of $5.55. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, counting checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company’s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company’s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, comprises various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Ironwood Pharmaceuticals, Inc (NASDAQ:IRWD), enhanced 4.79%, and closed at $16.41. The stock volatility for the week is 4.73%, while for the month remained 4.21%. The company holds consensus target price of $15.88.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.39diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 40.90% and Annual EPS growth for the past 5 years is considered as 30.30%.
The mean recommendation of analysts for this stock is 2.80. (where 1=Buy, 5=Sale).
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnership agreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau. The company also has license agreements with Almirall, S.A. and Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, in addition to Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals Inc (NASDAQ:AGIO), rose 4.69%, and closed at $110.96. The company has the market capitalization of $3.94B. On the other hand the stock’s volatility for the week is 3.60%, and for the month is 3.47%. The stock’s price to book ratio is 9.19, however price to sale ratio is 63.15. Analyst’s mean recommendation regarding this stock is 2.30. (where 1=Buy, 5=Sale).
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates comprise AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK deficiency. The company has a partnershipand license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
